ADMA
Adma Biologics Inc
NASDAQ · Biotechnology
$16.43
+0.49 (+3.07%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 417.09M | 239.65M | 937.52M | 922.90M | 1.03B |
| Net Income | 193.33M | 99.97M | -79,968,646 | -95,808,796 | -87,264,834 |
| EPS | — | — | — | — | — |
| Profit Margin | 46.4% | 44.0% | -8.5% | -10.4% | -8.5% |
| Rev Growth | +74.0% | +74.0% | +21.3% | +20.1% | +10.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 335.71M | 335.71M | 1.55B | 1.56B | 1.50B |
| Total Equity | 1.62B | 1.62B | 2.74B | 2.42B | 2.53B |
| D/E Ratio | 0.21 | 0.21 | 0.57 | 0.64 | 0.59 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 134.90M | 73.63M | -111,424,845 | -107,012,515 | -125,992,506 |
| Free Cash Flow | — | — | -94,542,550 | -83,155,340 | -96,884,239 |